Neuphoria Therapeutics (NEUP) Gains from Sales and Divestitures (2025 - 2026)
Neuphoria Therapeutics (NEUP) reported Gains from Sales and Divestitures of $13476.0 for Q1 2026, down 60.27% on a QoQ basis from $33915.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) has 2 years of Gains from Sales and Divestitures data on file, last reported at $13476.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13,476.00 |
| Mar 31, 2026 | 13,476.00 |
| Dec 31, 2025 | 33,915.00 |
| Dec 31, 2025 | 33,915.00 |